Table 2 Paclitaxel pharmacokinetic parameters.

From: Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

  Median (range) P - value a
Australian cohort Dutch cohort
Dose (mg) 290 (220–350) 320 (230–390) <0.001
Infusion time (h) 3.2 (2.8–3.9) 3.4 (2.5–4.5) 0.224
Infusion rate (mg/h) 90 (71–110) 98 (63–135) 0.153
CL at the end of infusion (L/h) 9.9 (5.2–17.3) 11.2 (5.2–20.5) 0.209
TC>0.05 (h) 30.3 (21.0–47.3) 27.8 (20.5–46.0) 0.094
AUC0-24 (mg/L*h) 16.4 (10.5–26.1) 15.3 (11.3–27.1) 0.402
Cmax (mg/L) 4.9 (3.2–7.5) 4.9 (3.0–8.9) 1.000
  1. aP-values were based on the independent sample median test.
  2. Abbreviations: CL, clearance; TC>0.05, time of paclitaxel concentration >0.05 µmol/L; AUC0-24, area under concentration-time curve of the first 24 hours; Cmax, maximum paclitaxel concentration.